ID

12768

Description

Trial of Sirolimus and Methotrexate in Relapsed/Refractory Lymphoblastic Leukemia and Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01162551

Lien

https://clinicaltrials.gov/show/NCT01162551

Mots-clés

Versions (1)
  1. 21/12/2015 21/12/2015 -
Téléchargé le

21 décembre 2015

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY 4.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

Eligibility Cancer NCT01162551

Anglais

Eligibility Cancer NCT01162551

1 Formulaires  
  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01162551
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients </= 25 years of age, at time of enrollment, with second or greater relapse of all or nhl. for all must have histologic diagnosis with >10% blasts in the marrow and for lymphoblastic lymphoma or peripheral t-cell lymphoma must have radiologic or physical evidence of recurrence.
Description

age; Acute lymphocytic leukemia; recurrence

Type de données

boolean

Alias
UMLS CUI [1]
C0001779
UMLS CUI [2]
C0023449
UMLS CUI [3]
C0034897
lansky > 50% or karnofsky > 50%
Description

Lansky Play-Performance Status; Karnofsky Performance Status

Type de données

boolean

Alias
UMLS CUI [1]
C1522275
UMLS CUI [2]
C0206065
negative pregnancy test
Description

Pregnancy test negative

Type de données

boolean

Alias
UMLS CUI [1]
C0427780
creatinine clearance or radioisotope gfr > 70ml/min/m2 or serum creatinine based on age /gender
Description

creatinine clearance; age; gender

Type de données

boolean

Alias
UMLS CUI [1]
C0373595
UMLS CUI [2]
C0001779
UMLS CUI [3]
C0079399
pulse ox >94%
Description

pulse oximetry

Type de données

boolean

Alias
UMLS CUI [1]
C0034108
total bilirubin <1.5 x normal for age
Description

total bilirubin

Type de données

boolean

Alias
UMLS CUI [1]
C0201913
alt < 5 x normal for age
Description

Alanine Transaminase

Type de données

boolean

Alias
UMLS CUI [1]
C1557189
albumin > 2g/dl
Description

albumin

Type de données

boolean

Alias
UMLS CUI [1]
C0201838
shortening fraction by echo > 28% or ejection fraction > 50% by gated radionuclide study
Description

ejection fraction

Type de données

boolean

Alias
UMLS CUI [1]
C0489482
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
patient has known allergies to sirolimus,fk-506 or mtor inhibitors
Description

hypersensitivity sirolimus

Type de données

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0072980
patient is taking other investigational anti-neoplastic drugs
Description

investigational anti-neoplastic drugs other

Type de données

boolean

Alias
UMLS CUI [1]
C1875339
patient received no myelosuppressive chemo within 14 days
Description

chemotherapy myelosuppressive

Type de données

boolean

Alias
UMLS CUI [1,1]
C3665472
UMLS CUI [1,2]
C1513793
< 14 days have elapsed since local palliative xrt (small port) < 28 days since prior craniospinal xrt or 50% radiation of pelvis <28 days if other substantial bm radiation
Description

radiotherapy palliative

Type de données

boolean

Alias
UMLS CUI [1,1]
C0034619
UMLS CUI [1,2]
C1285530
hematopoietic growth factors within 7 days of entry (except erythropoietin.)
Description

hematopoietic growth factors

Type de données

boolean

Alias
UMLS CUI [1]
C0079490
patient has taken any biologic agents within 14 days
Description

drug biologic

Type de données

boolean

Alias
UMLS CUI [1,1]
C0013227
UMLS CUI [1,2]
C0205460
post bmt/sct - evidence of active gvhd, at least > 3 months must have elapsed
Description

Graft-versus-host disease

Type de données

boolean

Alias
UMLS CUI [1]
C0018133
patient has uncontrolled infection (if patients with fungal disease, stable for < 14 days and patients with bacteremia without negative blood culture
Description

bacteremia; infection uncontrolled

Type de données

boolean

Alias
UMLS CUI [1]
C0004610
UMLS CUI [2,1]
C3714514
UMLS CUI [2,2]
C0205318
existing non-hematologic toxicities > grade 2
Description

toxicity

Type de données

boolean

Alias
UMLS CUI [1]
C0600688
use of steroids or hydroxyurea is permitted upto 14 days prior to entry.
Description

steroids; hydroxyurea

Type de données

boolean

Alias
UMLS CUI [1]
C0038317
UMLS CUI [2]
C0020402
Retour au début de la page

Similar models

Eligibility Cancer NCT01162551

1 Formulaires
  1. StudyEvent: Eligibility
    1. Eligibility Cancer NCT01162551
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
C1512693 (UMLS CUI)
age; Acute lymphocytic leukemia; recurrence
Item
patients </= 25 years of age, at time of enrollment, with second or greater relapse of all or nhl. for all must have histologic diagnosis with >10% blasts in the marrow and for lymphoblastic lymphoma or peripheral t-cell lymphoma must have radiologic or physical evidence of recurrence.
boolean
C0001779 (UMLS CUI [1])
C0023449 (UMLS CUI [2])
C0034897 (UMLS CUI [3])
Lansky Play-Performance Status; Karnofsky Performance Status
Item
lansky > 50% or karnofsky > 50%
boolean
C1522275 (UMLS CUI [1])
C0206065 (UMLS CUI [2])
Pregnancy test negative
Item
negative pregnancy test
boolean
C0427780 (UMLS CUI [1])
creatinine clearance; age; gender
Item
creatinine clearance or radioisotope gfr > 70ml/min/m2 or serum creatinine based on age /gender
boolean
C0373595 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
C0079399 (UMLS CUI [3])
pulse oximetry
Item
pulse ox >94%
boolean
C0034108 (UMLS CUI [1])
total bilirubin
Item
total bilirubin <1.5 x normal for age
boolean
C0201913 (UMLS CUI [1])
Alanine Transaminase
Item
alt < 5 x normal for age
boolean
C1557189 (UMLS CUI [1])
albumin
Item
albumin > 2g/dl
boolean
C0201838 (UMLS CUI [1])
ejection fraction
Item
shortening fraction by echo > 28% or ejection fraction > 50% by gated radionuclide study
boolean
C0489482 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
hypersensitivity sirolimus
Item
patient has known allergies to sirolimus,fk-506 or mtor inhibitors
boolean
C0020517 (UMLS CUI [1,1])
C0072980 (UMLS CUI [1,2])
investigational anti-neoplastic drugs other
Item
patient is taking other investigational anti-neoplastic drugs
boolean
C1875339 (UMLS CUI [1])
chemotherapy myelosuppressive
Item
patient received no myelosuppressive chemo within 14 days
boolean
C3665472 (UMLS CUI [1,1])
C1513793 (UMLS CUI [1,2])
radiotherapy palliative
Item
< 14 days have elapsed since local palliative xrt (small port) < 28 days since prior craniospinal xrt or 50% radiation of pelvis <28 days if other substantial bm radiation
boolean
C0034619 (UMLS CUI [1,1])
C1285530 (UMLS CUI [1,2])
hematopoietic growth factors
Item
hematopoietic growth factors within 7 days of entry (except erythropoietin.)
boolean
C0079490 (UMLS CUI [1])
drug biologic
Item
patient has taken any biologic agents within 14 days
boolean
C0013227 (UMLS CUI [1,1])
C0205460 (UMLS CUI [1,2])
Graft-versus-host disease
Item
post bmt/sct - evidence of active gvhd, at least > 3 months must have elapsed
boolean
C0018133 (UMLS CUI [1])
bacteremia; infection uncontrolled
Item
patient has uncontrolled infection (if patients with fungal disease, stable for < 14 days and patients with bacteremia without negative blood culture
boolean
C0004610 (UMLS CUI [1])
C3714514 (UMLS CUI [2,1])
C0205318 (UMLS CUI [2,2])
toxicity
Item
existing non-hematologic toxicities > grade 2
boolean
C0600688 (UMLS CUI [1])
steroids; hydroxyurea
Item
use of steroids or hydroxyurea is permitted upto 14 days prior to entry.
boolean
C0038317 (UMLS CUI [1])
C0020402 (UMLS CUI [2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial